HE UNITED STATES PATENT AND TRADEMARK OFFICE

Re:

Applicants: Aurora Brieva Delgado, et al.

Information Disclosure Statement

U.S. Appln. No.: 09/913,351

2 5 2002

Group: not yet assigned

U.S. Filing Date: August 13, 2001

Examiner: not yet assigned

International Application No: PCT/ES99/00338

International Filing Date: 21 October 1999

Our Ref.: B-4275PCT 618999-1

For: "PHARMACOLOGICALLY ACTIVE POLYPEPTIDE GLYCOCONJUGATES"

) Date: February 5, 2002

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In accordance with the Applicants' duty to disclose information which may be material to the examination of the above-identified application, the undersigned respectfully requests that the Examiner consider on the merits the documents listed on the enclosed Form PTO-1449 (modified) before issuing the first Office Action on the merits. We are enclosing herewith a copy of each document listed on the enclosed Form PTO-1449 (modified).

The documents listed on Form-1449 (modified) are those cited in the International Search Report (2 pages) of PCT Application No. PCT/ES99/00338. A copy of the International Search Report is enclosed herewith.

French Patent Document No. FR 2691465 A1 is in French. English-language explanation of the relevance of French Patent Document No. FR 2691465 Al can be found in the enclosed International Search Report for PCT Application No. PCT/ES99/00338.

The filing of this Information Disclosure Statement (IDS) shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The Applicants believe that this IDS is being submitted before the

Information Disclosure Statement USSN 09/913,351 February 5, 2002 Page 2

issuance of a first Office Action on the merits and before the issuance of a Final Rejection or Notice of Allowance. Therefore, no official fees should be due; and this IDS should be considered on the merits. If this IDS is being submitted after the issuance of the first Office Action on the merits and before the issuance of a Final Rejection or Notice of Allowance, then the Commissioner is authorized to charge Deposit Account No. 12-0415 \$180.00 (or any other required amount), which is the fee set forth in 37 C.F.R. § 1.97(c); and this IDS should be fully considered on the merits, in accordance with 37 C.F.R. § 1.97(d). If this IDS is being submitted after the issuance of a Final Rejection or Notice of Allowance, then the Commissioner is not authorized to charge \$180.00 to Deposit Account No. 12-0415.

The filing of this IDS shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

The person making this statement is the practitioner who signs below on the basis of information supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)) and on the basis of information in the practitioner's file.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to the "Hon. Commissioner of Patents and Trademarks, Washington, p.C. 20231",

on February 5, 2002 by Suzanne Johnston.

Respectfully submitted,

John Palmer \\
Attorney for Applicant Reg. No. 36,885

LADAS & PARRY 5670 Wilshire Boulevard Suite 2100 Los Angeles, CA 90036 (323) 934-2300

Enclosures: Form PTO-1449 (modified) (1 page)

Copy of International Search Report for PCT/ES99/00338 (2 pages)

A copy of each document that is listed on Form PTO-1449 (modified)